Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease

Neurobiology of Aging

Volumn 35, Issue 2, 2014, Pages 271-278

  Whiley, Luke ^a   Sen, Arundhuti ^a   Heaton, James ^a   Proitsi, Petroula ^a   García Gómez, Diego ^b   Leung, Rufina ^a   Smith, Norman ^a   Thambisetty, Madhav ^c   Kloszewska, Iwona ^d   Mecocci, Patrizia ^e   Soininen, Hilkka ^f   Tsolaki, Magda ^g   Vellas, Bruno ^h   Lovestone, Simon ^a   Legido Quigley, Cristina ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF SALAMANCA   (Spain)

^c NATIONAL INSTITUTE ON AGING   (United States)

^d MEDICAL UNIVERSITY OF LODZ   (Poland)

^e UNIVERSITY OF PERUGIA   (Italy)

^f KUOPIO UNIVERSITY HOSPITAL   (Finland)

^g ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^h Aristotle University of Thessaloniki ^*  (France)

Author keywords

Addneuromed; Alzheimer's disease; ApoE; Lipid; Mild cognitive impairment; Phosphatidylcholine; Plasma

Indexed keywords

APOLIPOPROTEIN E; FATTY ACID; LIPID; PHOSPHATIDYLCHOLINE;

ALZHEIMER DISEASE; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; LIPID BLOOD LEVEL; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; MILD COGNITIVE IMPAIRMENT; NUCLEAR MAGNETIC RESONANCE; PHOSPHATIDYLCHOLINE METABOLISM; PHOSPHOLIPID METABOLISM; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; VALIDATION STUDY;

ADDNEUROMED; ALZHEIMER'S DISEASE; APOE; LIPID; MILD COGNITIVE IMPAIRMENT; PHOSPHATIDYLCHOLINE; PLASMA;

ALZHEIMER DISEASE; APOLIPOPROTEINS E; CHROMATOGRAPHY, LIQUID; COHORT STUDIES; FATTY ACIDS, UNSATURATED; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MASS SPECTROMETRY; MILD COGNITIVE IMPAIRMENT; PHOSPHATIDYLCHOLINES; PREDICTIVE VALUE OF TESTS; ROC CURVE;

EID: 84887232805     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2013.08.001     Document Type: Article

References (49)

1. Ashford J.W. APOE genotype effects on Alzheimer's disease onset and epidemiology. J.Mol. Neurosci. 2004, 23:157-165.
2. Biagioni M.C., Galvin J.E. Using biomarkers to improve detection of Alzheimer's disease. Neurodegener. Dis. Manag. 2011, 1:127-139.
3. Bradley M.A., Xiong-Fister S., Markesbery W.R., Lovell M.A. Elevated 4-hydroxyhexenal in Alzheimer's disease (AD) progression. Neurobiol. Aging 2012, 33:1034-1044.
4. Carrola J., Rocha C.M., Barros A.S., Gil A.M., Goodfellow B.J., Carreira I.M., Bernardo J., Gomes A., Sousa V., Carvalho L., Duarte I.F. Metabolic signatures of lung cancer in biofluids: NMR-based metabonomics of urine. J.Proteome Res. 2011, 10:221-230.
5. Colangelo V., Schurr J., Ball M.J., Pelaez R.P., Bazan N.G., Lukiw W.J. Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: transcription and neurotrophic factor down-regulation and up-regulation of apoptotic and pro-inflammatory signaling. J.Neurosci. Res. 2002, 70:462-473.
6. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association, National Institute of Aging Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". Neurobiol. Aging 1998, 19:109-116.
7. Cramer P.E., Cirrito J.R., Wesson D.W., Lee C.Y., Karlo J.C., Zinn A.E., Casali B.T., Restivo J.L., Goebel W.D., James M.J., Brunden K.R., Wilson D.A., Landreth G.E. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 2012, 335:1503-1506.
8. Dennis E.A., Cao J., Hsu Y.H., Magrioti V., Kokotos G. Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. Chem. Rev. 2011, 111:6130-6185.
9. Di Paolo G., Kim T.W. Linking lipids to Alzheimer's disease: cholesterol and beyond. Nature. Rev. Neurosci. 2011, 12:284-296.
10. Duarte I.F., Legido-Quigley C., Parker D.A., Swann J.R., Spraul M., Braumann U., Gil A.M., Holmes E., Nicholson J.K., Murphy G.M., Vilca-Melendez H., Heatond N., Lindon J.C. Identification of metabolites in human hepatic bile using 800 MHz H-1 NMR spectroscopy, HPLC-NMR/MS and UPLC-MS. Mol. Biosyst. 2009, 5:180-190.
11. Dyrks T., Weidemann A., Multhaup G., Salbaum J.M., Lemaire H.G., Kang J., Mullerhill B., Masters C.L., Beyreuther K. Identification, transmembrane orientation and biogenesis of the amyloid A4 precursor of Alzheimers-disease. EMBO J. 1988, 7:949-957.
12. Frisardi V., Panza F., Seripa D., Farooqui T., Farooqui A.A. Glycerophospholipids and glycerophospholipid-derived lipid mediators: a complex meshwork in Alzheimer's disease pathology. Prog. Lipid Res. 2011, 50:313-330.
13. Gattaz W.F., Cairns N.J., Levy R., Forstl H., Braus D.F., Maras A. Decreased phospholipase A2 activity in the brain and in platelets of patients with Alzheimer's disease. Eur. Arch. Psychiatry Clin. Neurosci. 1996, 246:129-131.
14. Gattaz W.F., Maras A., Cairns N.J., Levy R., Forstl H. Decreased phospholipase A2 activity in Alzheimer brains. Biol. Psychiatry 1995, 37:13-17.
15. Gaudin M., Panchal M., Auzeil N., Duyckaerts C., Brunelle A., Laprevote O., Touboul D. Choline-containing phospholipids in microdissected human Alzheimer's disease brain senile plaque versus neuropil. Bioanalysis 2012, 4:2153-5159.
16. Gonzalez-Dominguez R., Garcia-Barrera T., Gomez-Ariza J.L. Metabolomic approach to Alzheimer's disease diagnosis based on mass spectrometry. Chem. Pap. 2012, 66:829-835.
17. Greenberg N., Grassano A., Thambisetty M., Lovestone S., Legido-Quigley C. Aproposed metabolic strategy for monitoring disease progression in Alzheimer's disease. Electrophoresis 2009, 30:1235-1239.
18. Han X.L., Rozen S., Boyle S.H., Hellegers C., Cheng H., Burke J.R., Welsh-Bohmer K.A., Doraiswamy P.M., Kaddurah-Daouk R. Metabolomics in early Alzheimer's disease: identification of altered plasma sphingolipidome using shotgun lipidomics. PLoS One 2011, 6:e21643.
19. Hye A., Lynham S., Thambisetty M., Causevic M., Campbell J., Byers H.L., Hooper C., Rijsdijk F., Tabrizi S.J., Banner S., Shaw C.E., Foy C., Poppe M., Archer N., Hamilton G., Powell J., Brown R.G., Sham P., Ward M., Lovestone S. Proteome-based plasma biomarkers for Alzheimer's disease. Brain 2006, 129:3042-3050.
20. Jack C.R., Albert M.S., Knopman D.S., McKhann G.M., Sperling R.A., Carrillo M.C., Thies B., Phelps C.H. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:257-262.
21. Kantarci K., Weigand S.D., Petersen R.C., Boeve B.F., Knopman D.S., Gunter J., Reyes D., Shiung M., O'Brien P.C., Smith G.E., Ivnik R.J., Tangalos E.G., Jack C.R. Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer's disease. Neurobiol. Aging 2007, 28:1330-1339.
22. Lee J.C., Simonyi A., Sun A.Y., Sun G.Y. Phospholipases A2 and neural membrane dynamics: implications for Alzheimer's disease. J.Neurochem. 2011, 116:813-819.
23. Li Z., Vance D.E. Phosphatidylcholine and choline homeostasis. J.Lipid Res. 2008, 49:1187-1194.
24. Lovestone S., Anderton B.H., Hartley C., Jensen T.G., Jorgensen A.L. The intracellular fate of apolipoprotein E is tau dependent and apoe allele-specific. Neuroreport 1996, 7:1005-1008.
25. Lovestone S., Francis P., Kloszewska I., Mecocci P., Simmons A., Soininen H., Spenger C., Tsolaki M., Vellas B., Wahlund L.O., Ward M. AddNeuroMed-the European collaboration for the discovery of novel biomarkers for Alzheimer's disease. Ann. N. Y. Acad. Sci. 2009, 1180:36-46.
26. Luft F.C. Alzheimer's disease, blood lipids, and heart disease: what are the interrelationships?. J.Mol. Med. 1997, 75:73-74.
27. Mangialasche F., Xu W.L., Kivipelto M., Costanzi E., Ercolani S., Pigliautile M., Cecchetti R., Baglioni M., Simmons A., Soininen H., Tsolaki M., Kloszewska I., Vellas B., Lovestone S., Mecocci P., Consortium A. Tocopherols and tocotrienols plasma levels are associated with cognitive impairment. Neurobiol. Aging 2012, 33:2282-2290.
28. Martin F.P., Dumas M.E., Wang Y., Legido-Quigley C., Yap I.K., Tang H., Zirah S., Murphy G.M., Cloarec O., Lindon J.C., Sprenger N., Fay L.B., Kochhar S., van Bladeren P., Holmes E., Nicholson J.K. Atop-down systems biology view of microbiome-mammalian metabolic interactions in a mouse model. Mol. Syst. Biol. 2007, 3:112.
29. Mayeux R., Stern Y. Epidemiology of Alzheimer disease. Cold Spring Harbor Perspect. Med. 2012, 2:a006239.
30. Orešič M., Hyötyläinen T., Herukka S.K., Sysi-Aho M., Mattila I., Seppänan-Laakso T., Julkunen V., Gopalacharyulu P.V., Hallikainen M., Koikkalainen J., Kivipelto M., Helisalmi S., Lötjönen J., Soininen H. Metabolome in progression to Alzheimer's disease. Transl. Psychiatry 2011, 1:e57.
31. Pericak-Vance M.A., Bebout J.L., Gaskell P.C., Yamaoka L.H., Hung W.Y., Alberts M.J., Walker A.P., Bartlett R.J., Haynes C.A., Welsh K.A., Earl N.L., Heyman A., Clark C.M., Roses A.D. Linkage studies in familial Alzheimer disease: evidence for chromosome 19 linkage. Am. J. Hum. Genet. 1991, 48:1034-1050.
32. Perttu E.K., Kohli A.G., Szoka F.C. Inverse-phosphocholine lipids: a remix of a common phospholipid. J.Am. Chem. Soc. 2012, 134:4485-4488.
33. Pettegrew J.W., Panchalingam K., Moossy J., Martinez J., Rao G., Boller F. Correlation of P-31 magnetic-resonance spectroscopy and morphologic findings in Alzheimers-disease. Arch. Neurol. 1988, 45:1093-1096.
34. Rainville P.D., Stumpf C.L., Shockcor J.P., Plumb R.S., Nicholson J.K. Novel application of reversed-phase UPLC-oaTOF-MS for lipid analysis in complex biological mixtures: a new tool for lipidomics. J.Proteome Res. 2007, 6:552-558.
35. Ross B.M., Moszczynska A., Erlich J., Kish S.J. Phospholipid-metabolizing enzymes in Alzheimer's disease: increased lysophospholipid acyltransferase activity and decreased phospholipase A2 activity. J.Neurochem. 1998, 70:786-793.
36. Ryan S.D., Whitehead S.N., Swayne L.A., Moffat T.C., Hou W., Ethier M., Bourgeois A.J., Rashidian J., Blanchard A.P., Fraser P.E., Park D.S., Figeys D., Bennett S.A. Amyloid-beta42 signals tau hyperphosphorylation and compromises neuronal viability by disrupting alkylacylglycerophosphocholine metabolism. Proc. Natl. Acad. Sci. U.S.A 2009, 106:20936-20941.
37. Salm P., Taylor P.J., Kostner K. Simultaneous quantification of total eicosapentaenoic acid, docosahexaenoic acid and arachidonic acid in plasma by high-performance liquid chromatography-tandem mass spectrometry. Biomed. Chromatogr. 2011, 25:652-659.
38. Sanchez-Mejia R.O., Mucke L. Phospholipase A2 and arachidonic acid in Alzheimer's disease. Biochim. Biophys. Acta. 2010, 1801:784-790.
39. Schaeffer E.L., da Silva E.R., Novaes Bde A., Skaf H.D., Gattaz W.F. Differential roles of phospholipases A2 in neuronal death and neurogenesis: implications for Alzheimer disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 34:1381-1389.
40. Selvy P.E., Lavieri R.R., Lindsley C.W., Brown H.A. Phospholipase D: enzymology, functionality, and chemical modulation. Chem. Rev. 2011, 111:6064-6119.
41. Shi H., Belbin O., Medway C., Brown K., Kalsheker N., Carrasquillo M., Proitsi P., Powell J., Lovestone S., Goate A., Younkin S., Passmore P., Morgan K. Genetic variants influencing human aging from late-onset Alzheimer's disease (LOAD) genome-wide association studies (GWAS). Neurobiol. Aging 2012, 33:1849e5-1849e18.
42. Simmons A., Westman E., Muehlboeck S., Mecocci P., Vellas B., Tsolaki M., Kloszewska I., Wahlund L.O., Soininen H., Lovestone S., Evans A., Spenger C., Consortium A. MRI measures of Alzheimer's disease and the AddNeuroMed Study. Ann. N. Y. Acad. Sci. 2009, 1180:47-55.
43. Small D.H., Maksel D., Kerr M.L., Ng J., Hou X., Chu C., Mehrani H., Unabia S., Azari M.F., Loiacono R., Aguilar M.I., Chebib M. The beta-amyloid protein of Alzheimer's disease binds to membrane lipids but does not bind to the alpha 7 nicotinic acetylcholine receptor. J.Neurochem. 2007, 101:1527-1538.
44. Talbot K., Young R.A., Jolly-Tornetta C., Lee V.M., Trojanowski J.Q., Wolf B.A. Afrontal variant of Alzheimer's disease exhibits decreased calcium-independent phospholipase A2 activity in the prefrontal cortex. Neurochem. Int. 2000, 37:17-31.
45. Thambisetty M., Simmons A., Velayudhan L., Hye A., Campbell J., Zhang Y., Wahlund L.O., Westman E., Kinsey A., Guntert A., Proitsi P., Powell J., Causevic M., Killick R., Lunnon K., Lynham S., Broadstock M., Choudhry F., Howlett D.R., Williams R.J., Sharp S.I., Mitchelmore C., Tunnard C., Leung R., Foy C., O'Brien D., Breen G., Furney S.J., Ward M., Kloszewska I., Mecocci P., Soininen H., Tsolaki M., Vellas B., Hodges A., Murphy D.G., Parkins S., Richardson J.C., Resnick S.M., Ferrucci L., Wong D.F., Zhou Y., Muehlboeck S., Evans A., Francis P.T., Spenger C., Lovestone S. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch. Gen. Psychiatry 2010, 67:739-748.
46. Wang D.C., Sun C.H., Liu L.Y., Sun X.H., Jin X.W., Song W.L., Liu X.Q., Wan X.L. Serum fatty acid profiles using GC-MS and multivariate statistical analysis: potential biomarkers of Alzheimer's disease. Neurobiol. Aging 2012, 33:1057-1066.
47. Whiley L., Godzien J., Ruperez F.J., Legido-Quigley C., Barbas C. In-vial dual extraction for direct LC-MS analysis of plasma for comprehensive and highly reproducible metabolic fingerprinting. Anal. Chem. 2012, 84:5992-5999.
48. Whiley L., Legido-Quigley C. Current strategies in the discovery of small-molecule biomarkers for Alzheimer's disease. Bioanalysis 2011, 3:1121-1142.
49. Zhao Y.Y., Xiong Y., Curtis J.M. Measurement of phospholipids by hydrophilic interaction liquid chromatography coupled to tandem mass spectrometry: the determination of choline containing compounds in foods. J.Chromatogr. A 2011, 1218:5470-5479.